Patients receiving idelalisib versus those receiving placebo had improved rates of overall response ( @ % vs. @ % ; odds ratio , @ ; P < @ ) and overall survival at @ months ( @ % vs. @ % ; hazard ratio for death , @ ; P = @ ) .